The Systemic Juvenile Idiopathic Arthritis Cohort of the Childhood Arthritis and Rheumatology Research Alliance Registry: 2010-2013
- PMID: 27307527
- DOI: 10.3899/jrheum.150997
The Systemic Juvenile Idiopathic Arthritis Cohort of the Childhood Arthritis and Rheumatology Research Alliance Registry: 2010-2013
Erratum in
-
The Systemic Juvenile Idiopathic Arthritis Cohort of the Childhood Arthritis and Rheumatology Research Alliance Registry: 2010-2013.J Rheumatol. 2016 Aug;43(8):1618. doi: 10.3899/jrheum.150997.C1. J Rheumatol. 2016. PMID: 27481994 No abstract available.
Abstract
Objective: We aimed to identify the (1) demographic/clinical characteristics, (2) medication usage trends, (3) variables associated with worse disease activity, and (4) characteristics of patients with persistent chronic arthritis in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Legacy Registry's systemic juvenile idiopathic arthritis (sJIA) cohort.
Methods: Demographics, disease activity measures, and medications at enrollment of patients with sJIA in the CARRA Registry were analyzed using descriptive statistics. Multivariate analyses were conducted to identify associations with increased disease activity. Medication usage frequencies were calculated by year.
Results: There were 528 patients with sJIA enrolled in the registry (2010-2013). There were 435 patients who had a complete dataset; of these, 372 met the International League of Associations for Rheumatology criteria and were included in the analysis. At enrollment, median disease duration and joint count were 3.7 years and 0, respectively; 16.4% had a rash and 6.7% had a fever. Twenty-six percent were taking interleukin 1 (IL-1) inhibitors and 29% glucocorticoids. Disease-modifying antirheumatic drugs and tumor necrosis factor inhibitors use decreased, while IL-6 inhibitor use increased between 2010 and 2013. African American patients had worse joint counts (p = 0.003), functional status (p = 0.01), and physician's global assessment (p = 0.008). Of the 255 subjects with > 2 years of disease duration, 56% had no arthritis or systemic symptoms, while 32% had persistent arthritis only.
Conclusion: Most patients in the largest sJIA cohort reported to date had low disease activity. Practice patterns for choice of biologic agents appeared to change over the study period. Nearly one-third had persistent arthritis without systemic symptoms > 2 years after onset. African Americans were associated with worse disease activity. Strategies are needed to improve outcomes in subgroups with poor prognosis.
Keywords: EPIDEMIOLOGY; SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS; TREATMENT.
Similar articles
-
Pilot study comparing the Childhood Arthritis & Rheumatology Research Alliance (CARRA) systemic Juvenile Idiopathic Arthritis Consensus Treatment Plans.Pediatr Rheumatol Online J. 2017 Apr 11;15(1):23. doi: 10.1186/s12969-017-0157-1. Pediatr Rheumatol Online J. 2017. PMID: 28399931 Free PMC article.
-
Bayesian comparative effectiveness study of four consensus treatment plans for initial management of systemic juvenile idiopathic arthritis: FiRst-Line Options for Systemic juvenile idiopathic arthritis Treatment (FROST).Clin Trials. 2018 Jun;15(3):268-277. doi: 10.1177/1740774518761367. Epub 2018 Mar 15. Clin Trials. 2018. PMID: 29542334 Free PMC article. Clinical Trial.
-
Practice and consensus-based strategies in diagnosing and managing systemic juvenile idiopathic arthritis in Germany.Pediatr Rheumatol Online J. 2018 Jan 22;16(1):7. doi: 10.1186/s12969-018-0224-2. Pediatr Rheumatol Online J. 2018. PMID: 29357887 Free PMC article.
-
Systemic Juvenile Idiopathic Arthritis.Pediatr Clin North Am. 2018 Aug;65(4):691-709. doi: 10.1016/j.pcl.2018.04.005. Pediatr Clin North Am. 2018. PMID: 30031494 Review.
-
Systemic Juvenile Idiopathic Arthritis: Diagnosis and Management.Indian J Pediatr. 2016 Apr;83(4):322-7. doi: 10.1007/s12098-016-2060-z. Epub 2016 Feb 26. Indian J Pediatr. 2016. PMID: 26916892 Review.
Cited by
-
Using genes to triangulate the pathophysiology of granulomatous autoinflammatory disease: NOD2, PLCG2 and LACC1.Int Immunol. 2018 Apr 25;30(5):205-213. doi: 10.1093/intimm/dxy021. Int Immunol. 2018. PMID: 29538758 Free PMC article. Review.
-
New frontiers in the treatment of systemic juvenile idiopathic arthritis.F1000Res. 2017 Jun 22;6:971. doi: 10.12688/f1000research.11327.1. eCollection 2017. F1000Res. 2017. PMID: 28690841 Free PMC article. Review.
-
Anakinra Drug Retention Rate and Predictive Factors of Long-Term Response in Systemic Juvenile Idiopathic Arthritis and Adult Onset Still Disease.Front Pharmacol. 2019 Aug 23;10:918. doi: 10.3389/fphar.2019.00918. eCollection 2019. Front Pharmacol. 2019. PMID: 31507416 Free PMC article.
-
A Bullseye for Children With Systemic Juvenile Idiopathic Arthritis.Arthritis Rheumatol. 2019 Jul;71(7):1030-1033. doi: 10.1002/art.40867. Epub 2019 May 27. Arthritis Rheumatol. 2019. PMID: 30802004 Free PMC article. No abstract available.
-
Pilot study comparing the Childhood Arthritis & Rheumatology Research Alliance (CARRA) systemic Juvenile Idiopathic Arthritis Consensus Treatment Plans.Pediatr Rheumatol Online J. 2017 Apr 11;15(1):23. doi: 10.1186/s12969-017-0157-1. Pediatr Rheumatol Online J. 2017. PMID: 28399931 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous